[A case of K-type-IgD myeloma (author's transl)]

Impact of claudin 18.2 expression on the efficacy of trastuzumab deruxtecan in patients with HER2-positive gastric or gastroesophageal junction cancer.

ESMO gastrointestinal oncology·2026

Safety and efficacy of first-line nivolumab plus chemotherapy for HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: real-world data analysis.

ESMO gastrointestinal oncology·2026

An open-label phase Ib/II study of trastuzumab deruxtecan combined with nivolumab and CAPOX for HER2-low gastroesophageal adenocarcinoma.

ESMO gastrointestinal oncology·2026

Real-world outcomes of trifluridine/tipiracil for heavily pretreated patients with advanced gastric cancer.

ESMO gastrointestinal oncology·2026

Temporal dynamics of CLDN18.2 expression following zolbetuximab treatment in advanced gastric cancer.

ESMO gastrointestinal oncology·2026

Clinical implementation of simultaneous multiple biomarkers testing for metastatic or recurrent gastroesophageal adenocarcinoma: a single-institutional experience.

ESMO gastrointestinal oncology·2026

[Treatment landscape of mature NK/T-cell lymphomas: treatment outcomes in Japan and future prospects].

[Rinsho ketsueki] The Japanese journal of clinical hematology·2026

[Prophylactic or pre-emptive therapy with azacitidine or FLT3 inhibitor after allogeneic hematopoietic stem cell transplantation for AML and MDS].

[Rinsho ketsueki] The Japanese journal of clinical hematology·2026

[Prophylactic use of tyrosine kinase inhibitors after allogeneic hematopoietic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia].

[Rinsho ketsueki] The Japanese journal of clinical hematology·2026

[Development of universal off-the-shelf T cell therapies derived from ES/iPS cells for leukemia and COVID-19].

[Rinsho ketsueki] The Japanese journal of clinical hematology·2026

[Predictors of treatment-free remission (TFR) and second TFR attempts in chronic myeloid leukemia].

[Rinsho ketsueki] The Japanese journal of clinical hematology·2026

[Complement-coagulation crosstalk in immunothrombosis].

[Rinsho ketsueki] The Japanese journal of clinical hematology·2026

[Sarcoidosis from an immunological perspective - experience-based diagnosis and treatment with targeted therapies].

Therapeutische Umschau. Revue therapeutique·2026

[Immune-related adverse events of immune checkpoint inhibitors].

Therapeutische Umschau. Revue therapeutique·2026

Therapeutic drug monitoring of adalimumab for dose optimization during maintenance therapy in patients with ulcerative colitis: real-world data.

Folia medica·2026

Correction: A robust and scalable immunoadsorbent platform based on the high-affinity M03-IgG antibody for targeted IL-6 Removal in cytokine storm.

Frontiers in immunology·2026

Expanded dendritic cells loaded with placental gp96 to generate antigen-specific T cells for anti-tumor immunity: an in vitro study.

Central-European journal of immunology·2026

Protein Posttranslational Modifications in Immunity: Molecular Mechanisms and Therapeutic Targets.

MedComm·2026

Related Experiment Videos

[A case of K-type-IgD myeloma (author's transl)]

Related Concept Videos

Impact of claudin 18.2 expression on the efficacy of trastuzumab deruxtecan in patients with HER2-positive gastric or gastroesophageal junction cancer.

Safety and efficacy of first-line nivolumab plus chemotherapy for HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: real-world data analysis.

An open-label phase Ib/II study of trastuzumab deruxtecan combined with nivolumab and CAPOX for HER2-low gastroesophageal adenocarcinoma.

Real-world outcomes of trifluridine/tipiracil for heavily pretreated patients with advanced gastric cancer.

Temporal dynamics of CLDN18.2 expression following zolbetuximab treatment in advanced gastric cancer.

Clinical implementation of simultaneous multiple biomarkers testing for metastatic or recurrent gastroesophageal adenocarcinoma: a single-institutional experience.

[Treatment landscape of mature NK/T-cell lymphomas: treatment outcomes in Japan and future prospects].

[Prophylactic or pre-emptive therapy with azacitidine or FLT3 inhibitor after allogeneic hematopoietic stem cell transplantation for AML and MDS].

[Prophylactic use of tyrosine kinase inhibitors after allogeneic hematopoietic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia].

[Development of universal off-the-shelf T cell therapies derived from ES/iPS cells for leukemia and COVID-19].

[Predictors of treatment-free remission (TFR) and second TFR attempts in chronic myeloid leukemia].

[Complement-coagulation crosstalk in immunothrombosis].

[Sarcoidosis from an immunological perspective - experience-based diagnosis and treatment with targeted therapies].

[Immune-related adverse events of immune checkpoint inhibitors].

Therapeutic drug monitoring of adalimumab for dose optimization during maintenance therapy in patients with ulcerative colitis: real-world data.

Correction: A robust and scalable immunoadsorbent platform based on the high-affinity M03-IgG antibody for targeted IL-6 Removal in cytokine storm.

Expanded dendritic cells loaded with placental gp96 to generate antigen-specific T cells for anti-tumor immunity: an in vitro study.

Protein Posttranslational Modifications in Immunity: Molecular Mechanisms and Therapeutic Targets.

Related Experiment Videos

[A case of K-type-IgD myeloma (author's transl)]

Related Concept Videos

Related Articles